查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2072254

動態療法市場（第二版）：按目標疾病、治療領域和主要地區分類的趨勢和預測（至2035年）

Photodynamic Therapy Market (2nd Edition) by Target Indication, Therapeutic Area, and Key Geographical Regions - Trends and Forecast, Till 2035
出版日期: | 出版商: Roots Analysis | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

動態療法市場概覽

根據 Roots Analysis 的研究，全球動態療法市場預計將從目前的 7.49 億美元成長到 2035 年的 15.32 億美元，在預測期內（到 2035 年）的複合年成長率為 8.3%。

光動力療法市場-IMG1

動態療法市場：成長與趨勢

動態療法（PDT），又稱光激活療法，是一種標靶性、微創治療方法，利用特定波長的光激活光敏物質。活化後，這些物質會產生細胞毒性活性氧（ROS），選擇性地破壞癌組織和其他病變組織。 PDT起源於20世紀初，經過數十年的臨床研究和技術進步，取得了顯著的改進。如今，PDT已發展成為腫瘤治療領域一種用途廣泛的治療方法，與傳統的化療和放射線治療相比，具有全身毒性更低等顯著優勢。此外，光敏物質（如卟啉複合物和奈米顆粒製劑）設計的不斷創新，以及先進的精準光照射系統，已將PDT的應用範圍從腫瘤治療擴展到抗菌和皮膚病治療等領域。

在動態療法中，光敏物質通常局部應用於腫瘤部位，從而最大限度地減少全身暴露，並降低長期皮膚光敏性和靶外毒性等副作用。此外，光動力療法在治療多種皮膚疾病方面已顯示出良好的臨床療效，包括日光性角化症、痤瘡、疣和水痘病變，這表明其適用於治療多種皮膚疾病。

受光激活療法相關治療益處的推動，許多相關人員正積極致力於開發新型光免疫療法和動態療法，以治療多種疾病。值得注意的是，目前已有超過70種療法處於臨床開發階段，多種以光動力療法為基礎的療法已獲得監管部門批准。此外，領導企業正擴大利用量子點等奈米技術平台作為下一代光敏劑，用於治療皮膚癌。隨著技術的不斷進步、臨床研究的不斷拓展以及人們對標靶治療日益成長的興趣，預計動態療法市場在預測期內將迎來顯著成長。

成長要素：市場擴張的策略促進因素

動態療法 (PDT) 市場的成長主要受全球癌症和皮膚疾病發病率上升的推動，這促使人們對標靶性強、微創療法的需求日益成長。 PDT 利用特定波長的光激活光敏物質，與傳統療法相比，能夠以最小的全身毒性實現精準的腫瘤切除。此外，光敏物質配方和光照射技術的不斷進步，包括高性能二極體雷射和光纖系統，顯著提高了動態療法的療效。這些創新使得藥物能夠更深地穿透組織，從而最佳化腫瘤治療效果。此外，PDT 在抗菌適應症和老齡化黃斑部病變(AMD) 方面的核准數量不斷增加，加上有利的醫保報銷機制，正在加速光激活療法的臨床應用。

市場挑戰：阻礙進展的主要障礙

動態療法 (PDT) 市場面臨許多挑戰，可能阻礙其廣泛應用。活化光源的組織穿透深度有限，限制了其在治療深部腫瘤和內臟惡性腫瘤的應用。此外，治療後光敏反應以及光療管理的需求會影響患者的依從性。先進光敏劑、專用光療系統和治療費用高昂，進一步限制了其普及，尤其是在新興市場。此外，人們對 PDT 益處的認知不足，以及對專用基礎設施和訓練有素的專業人員的需求，也持續阻礙其臨床應用。嚴格的監管要求以及來自免疫療法和標靶治療等替代療法的競爭，也為市場帶來了重大挑戰。

本報告檢視了全球動態療法市場，概述了市場和目標疾病，分析了影響市場成長的各種因素、市場規模趨勢和預測、按細分市場和地區進行的詳細分析、技術和產品趨勢、案例研究、資金籌措趨勢、競爭格局以及主要公司的概況。

目錄

第1章：序言

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

  • 章節概要
  • 市場動態
  • 結論

第5章摘要整理

第6章：引言

  • 光活化療法概述
  • 光療的類型
  • 光活化療法的組成部分
    • 光敏劑
    • 光源和設備
  • 光療的類型
    • 光免疫療法
    • 動態療法
    • 光熱治療
  • 動態療法和光熱治療的區別
  • 光活化療法的優勢

第7章 市場狀況

  • 章節概要
  • 光療：市場現狀
    • 不同類型光活化療法的分析
    • 依發展階段分析
    • 依所用光源類型進行分析
    • 依治療類型進行分析
    • 按給藥頻率分析
    • 依目標疾病進行分析
    • 按治療區域分析
    • 依治療領域和研發階段進行分析
  • 光激活療法研發公司：市場趨勢
    • 成立年份
    • 公司規模
    • 總部所在地（按地區）
    • 總部所在地（按國家/地區）

第8章：公司與藥物概況

  • 章節概要
  • ADVANZ PHARMA
  • Biofrontera
  • biolitec Pharma
  • Luzitin
  • Nanospectra Biosciences
  • photoatomic
  • Rakuten Medical
  • Impact Biotech
  • Theralase
  • Cetuximab Sarotalocan(R)
  • Alacare(R)
  • Ameluz(R)
  • Aminolevulinic Acid
  • Foscan(R) (Temoporfin)
  • FuMeiDa(R) (Hemoporfin)
  • Levulan Kerastick(R)
  • Metvixia(R) (Metvix)
  • Porfimer Sodium / Photofrin(R)
  • Verteporfin(R) (Visudyne

第9章：臨床試驗分析

  • 章節概要
  • 研究範圍和調查方法
  • 光激活療法：臨床試驗分析
    • 按考試報名年份
    • 按試驗註冊年份統計的註冊患者人數
    • 通過測試階段
    • 按試驗階段分類的註冊患者人數
    • 按考試狀態
    • 按考試報名年份及考試狀態
    • 按試驗狀態分類的註冊患者人數
    • 按目標患者群
    • 患者性別
    • 按贊助商/合作研究者類型
    • 透過測試設計
    • 最活躍的公司：臨床試驗數量
    • 區域分析

第10章 專利分析

  • 章節概要
  • 研究範圍和調查方法
  • 光激活療法：專利分析
    • 按專利類型分類
    • 按出版年份
    • 按專利類型及公開年份
    • 按申請年份
    • 按管轄權
    • 按申請人類型
    • 按專利取得年份
    • CPC符號
    • 產業領先公司：專利數量
    • 主要非工業企業：專利數量
    • 主要發明人：專利數量
  • 光激活療法：專利基準分析
    • 按專利特徵進行分析
    • 主要公司分析
  • 專利評估與分析

第11章 市場影響分析

  • 章節概要
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 結論

第12章：全球動態療法市場

  • 章節概要
  • 關鍵假設和調查方法
  • 全球動態療法市場：歷史趨勢與預測
  • 主要市場區隔

第13章動態療法市場：以目標疾病分類

  • 章節概要
  • 關鍵假設和調查方法
  • 動態療法市場：以標靶疾病分類
    • 日光性角化症
    • 攝護腺癌
    • 老齡化黃斑部病變
    • 頭頸部鱗狀細胞癌
    • 基底細胞癌
    • 葡萄酒肝血管瘤
    • 巴瑞特氏食道症
    • 食道癌
    • 支氣管癌
    • 肺癌
    • 鮑恩病
    • 腦腫瘤
    • 膀胱癌
    • T細胞淋巴瘤
    • 尿路上皮癌
  • 數據三角測量與檢驗

第14章動態療法市場：依治療領域分類

  • 章節概要
  • 關鍵假設和調查方法
  • 動態療法市場：依治療領域分類
    • 腫瘤性疾病
    • 皮膚病
    • 眼科疾病
  • 數據三角測量與檢驗

第15章動態療法市場：依主要區域分類

  • 章節概要
  • 關鍵假設和調查方法
  • 動態療法市場：主要區域分佈
    • 北美洲
    • 歐洲
    • 亞太地區
    • 中東和北非
  • 市場動態分析：重點區域
    • 滲透成長（PG）矩陣
    • 市場波動分析
  • 數據三角測量與檢驗

第16章 結論

第17章：高階主管洞見

第18章附錄一：表格形式數據

第19章 附錄二：公司與組織列表

區域市場機會分析

第20章 市場機會分析：北美

  • 按目標疾病分佈
  • 按治療區域分佈

第21章 市場機會分析：歐洲

  • 按目標疾病分佈
  • 按治療區域分佈

第22章 市場機會分析：亞太地區

  • 按目標疾病分佈
  • 按治療區域分佈

第23章 市場機會分析：中東與北非

  • 按目標疾病分佈
  • 按治療區域分佈

* 第20章至第23章的詳細資訊包含在報告隨附的Excel資料包中。 *

Product Code: RA100299

Photodynamic Therapy Market: Overview

As per Roots Analysis, the global photodynamic therapy market is estimated to grow from USD 749 million in the current year to USD 1,532 million by 2035, at a CAGR of 8.3% during the forecast period, till 2035.

Photodynamic Therapy Market - IMG1

Photodynamic Therapy Market: Growth and Trends

Light-activated therapy, commonly referred to as photodynamic therapy (PDT), is a targeted and minimally invasive treatment modality that utilizes photosensitizing agents activated by specific wavelengths of light. Upon activation, these agents generate cytotoxic reactive oxygen species (ROS), enabling the selective destruction of cancerous and other pathological tissues. Originating in the early 20th century, PDT has undergone substantial refinement through decades of clinical research and technological advancements. Over time, it has emerged as a versatile therapeutic approach for oncological indications, offering key advantages such as reduced systemic toxicity compared to conventional chemotherapy and radiotherapy. In addition, continuous innovations in photosensitizer design, including porphyrin-based conjugates and nanoparticle-based formulations, coupled with advanced precision light-delivery systems, have broadened the scope of PDT beyond oncology into antimicrobial and dermatological applications.

In photodynamic therapy, photosensitizers are typically administered locally at the tumor site, thereby minimizing systemic exposure and reducing adverse effects such as prolonged skin photosensitivity and off-target toxicity. Furthermore, PDT has demonstrated favorable clinical outcomes in the treatment of various dermatological conditions, including actinic keratosis, acne, warts, and microvesicular lesions, underscoring its suitability for managing a broad spectrum of skin disorders.

Driven by the therapeutic advantages associated with light-activated therapies, several industry stakeholders are actively undertaking initiatives to develop novel photo immunotherapies and photodynamic therapies targeting multiple disease indications. It is noteworthy that more than 70 therapies are currently under clinical development, while several PDT-based therapies have already received regulatory approval. Moreover, leading companies are increasingly leveraging nanotechnology platforms, such as quantum dots, as next-generation photosensitizers for the treatment of skin cancer. Owing to ongoing technological advancements, expanding clinical research efforts, and increasing interest in targeted therapeutic modalities, the photodynamic therapy market is anticipated to witness significant growth during the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The growth of the photodynamic therapy (PDT) market is primarily driven by the increasing global prevalence of cancer and dermatological disorders, which has intensified the demand for targeted and minimally invasive treatment approaches. PDT leverages photosensitizing agents activated by specific light wavelengths to enable precise tumor ablation while minimizing systemic toxicity compared to conventional therapeutic modalities. In addition, ongoing advancements in photosensitizer formulations and light-delivery technologies, including enhanced diode lasers and fiber-optic systems, have significantly improved the efficacy of photodynamic therapy. These innovations enable deeper tissue penetration and contribute to optimized treatment outcomes in oncology applications. Furthermore, the growing number of regulatory approvals for PDT across antimicrobial indications and age-related macular degeneration (AMD), coupled with favorable reimbursement frameworks, has accelerated the clinical adoption of light-activated therapies.

Market Challenges: Critical Barriers Impeding Progress

The photodynamic therapy (PDT) market faces several challenges that may hinder its widespread adoption. Limited tissue penetration of activating light sources restricts the treatment of deep-seated tumors and internal malignancies. Additionally, post-treatment photosensitivity and the need for controlled light exposure can impact patient compliance. The high cost of advanced photosensitizers, specialized light-delivery systems, and treatment procedures further limits accessibility, particularly in emerging markets. Moreover, the requirement for specialized infrastructure and trained professionals, coupled with limited awareness regarding PDT benefits, continues to constrain clinical adoption. Stringent regulatory requirements and competition from alternative therapies such as immunotherapy and targeted therapeutics also pose significant market challenges.

Photodynamic Therapy Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Target Indication

  • Actinic Keratosis
  • Prostate Cancer
  • Age-related Macular Degeneration
  • Head and Neck Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Port Wine Stain
  • Barrett's Esophagus
  • Esophageal Cancer
  • Endobronchial Cancer
  • Lung Cancer
  • Bowen's Disease
  • Brain Cancer
  • Bladder Cancer
  • T-cell Lymphoma
  • Urothelial Cancer

By Therapeutic Area

  • Oncological Disorders
  • Dermatological Disorders
  • Ophthalmic Disorders

By Key Geographical Regions

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Middle East and North Africa
  • Israel

Photodynamic Therapy Market: Key Segment Insights

Will the Oncological Disorders Segment Continue to Hold the Largest Market Share?

In the current year, the oncological disorders segment is expected to account for the largest share of the photodynamic therapy market (approximately 50%) and is projected to witness a relatively higher CAGR (11%) during the forecast period. This growth is primarily driven by the increasing global incidence of cancers, particularly skin, lung, esophageal, and head-and-neck cancers, which has accelerated the demand for PDT, owing to its targeted mechanism of selectively eliminating malignant cells through light-activated photosensitizers.

Which Target Indication Accounts for the Largest Photodynamic Therapy Market Share?

In the current year, the actinic keratosis segment is anticipated to capture the largest share of the light-activated therapy market (over 35%). This dominance can be attributed to the growing prevalence of actinic keratosis, a precancerous skin condition associated with prolonged ultraviolet (UV) exposure, along with the superior cosmetic outcomes offered by PDT compared to conventional treatment approaches such as cryotherapy.

It is worth highlighting that the head and neck squamous cell carcinoma segment is projected to grow at a comparatively higher CAGR during the forecast period. This growth is likely to be driven by the increasing global disease burden and ongoing clinical advancements, including the use of PDT in combination with immunotherapies, which have demonstrated promising response rates and reduced severe toxicities.

Regional Analysis: Which Regions are Expected to Witness the Fastest Growth in the Light-Activated Therapy Industry?

Europe: The Largest Regional Market

According to our photodynamic therapy market forecast, Europe is expected to account for the largest market share (nearly 50%) in the current year. The region's dominance can be attributed to the high prevalence of non-melanoma skin cancers, including actinic keratosis and basal cell carcinoma, which affect a significant portion of the population and continue to drive demand for PDT. Additionally, well-established healthcare systems across countries such as Germany, France, and the UK support the widespread adoption of outpatient PDT procedures through favorable reimbursement frameworks, national treatment guidelines, and ongoing clinical research focused on oncological and dermatological indications.

North America: The Fastest Growing Regional Market

The North American market is anticipated to witness the highest CAGR (14%) during the forecast period through 2035, according to our photodynamic therapy market analysis. modalities across the region. This growth is driven by increasing investments in pharmaceutical research and development, rapid technological advancements in light-based therapeutic systems, and strong government initiatives aimed at modernizing healthcare infrastructure. It is also supported by efforts to promote the adoption of advanced treatment modalities across the region.

Example Players in Photodynamic Therapy Market

  • ADVANZ PHARMA
  • Biofrontera
  • Biolitec Pharma
  • Galderma
  • Luzitin
  • Nanospectra Biosciences
  • Novartis
  • Rakuten Medical
  • Impact Biotech
  • Theralase

Photodynamic Therapy Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the photodynamic therapy market, focusing on key market segments, including [A] target indication, [B] therapeutic area, and [C] geographical regions.
  • Photodynamic Therapy Market Landscape: A detailed assessment of the overall photodynamic therapy market landscape, along with information on several relevant parameters, such as [A] stage of development, [B] type of light used, [C] type of therapy, [A] target indication, [B] Therapeutic area, [C] type of therapy, [D] company size, [E] year of establishment and [F] location of headquarters.
  • Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating cancer metabolism-based therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] trial study design, [F] type of sponsor, [G] patient gender, [H] most active industry, and non-industry players and [I] geographical distribution.
  • Patent Analysis: A detailed analysis of the patents that have been filed / granted based on important parameters such as, [A] type of patent, [B] publication year, [C] application year, [D] number of granted patents and patent applications, [E] patent jurisdiction, [F] CPC symbols, [G] patent age, [H] type of applicant, and [I] individual patent assignees (in terms of size of intellectual property portfolio).
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

  • Which are the leading companies in the photodynamic therapy market?
  • Which region dominates the photodynamic therapy market?
  • What are the key trends observed in photodynamic therapy market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by photodynamic therapy developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary PPT Insights Pack
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Overview of Light Activated Therapies
  • 6.2. Types of Light Activated Therapies
  • 6.3. Components of Light Activated Therapies
    • 6.3.1. Photosensitizing Substance
    • 6.3.2. Light Source and Device
  • 6.4. Type of Light Activated Therapy
    • 6.4.1. Photoimmunotherapy
      • 6.4.1.1 Mechanism of Action of Photoimmunotherapies
    • 6.4.2. Photodynamic Therapy
      • 6.4.2.1. Mechanism of Action of Photodynamic Therapy
      • 6.4.2.2. Advantages and Challenges Associated with Photodynamic Therapy
    • 6.4.3. Photothermal Therapy
      • 6.4.3.1. Mechanism of Action of Photothermal Therapy
  • 6.5. Difference between Photodynamic and Photothermal Therapy
  • 6.6. Advantages of Light Activated Therapies

7. MARKET LANDSCAPE

  • 7.1 Chapter Overview
  • 7.2. Light Activated Therapies: Overall Market Landscape
    • 7.2.1. Analysis by Type of Light Activated Therapy
    • 7.2.2. Analysis by Stage of Development
    • 7.2.3. Analysis by Type of Light Used
    • 7.2.4. Analysis by Type of Therapy
    • 7.2.5. Analysis by Dosing Frequency
    • 7.2.6. Analysis by Target Indication
    • 7.2.7. Analysis by Therapeutic Area
    • 7.2.8. Analysis by Therapeutic Area and Stage of Development
  • 7.3. Light Activated Therapy Developers: Overall Market Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters (Region)
    • 7.3.4. Analysis by Location of Headquarters (Country)

8. COMPANY AND DRUG PROFILES

  • 8.1. Chapter Overview
  • 8.2 ADVANZ PHARMA
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Product Portfolio
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Biofrontera
  • 8.4. biolitec Pharma
  • 8.5 Luzitin
  • 8.6 Nanospectra Biosciences
  • 8.7. photoatomic
  • 8.8. Rakuten Medical
  • 8.9. Impact Biotech
  • 8.10. Theralase
  • 8.11. Cetuximab Sarotalocan(R)
    • 8.11.1. Company Overview
    • 8.11.2. Drug Overview
    • 8.11.3. Clinical Development Status
    • 8.11.4. Clinical Trial Endpoints
    • 8.11.5. Dosage Regimen
    • 8.11.6. Key Insights
    • 8.11.7. Sales Revenue
  • 8.12. Alacare(R)
    • 8.12.1. Company Overview
    • 8.12.2. Drug Overview
    • 8.12.3. Clinical Development Status
    • 8.12.4. Clinical Trial Endpoints
    • 8.12.5. Dosage Regimen
    • 8.12.6. Key Insights
    • 8.12.7. Sales Revenue
  • 8.13. Ameluz(R)
    • 8.13.1. Company Overview
    • 8.13.2. Drug Overview
    • 8.13.3. Clinical Development Status
    • 8.13.4. Dosage Regimen
    • 8.13.5. Key Insights
    • 8.13.6. Sales Revenue
  • 8.14. Aminolevulinic Acid
    • 8.14.1. Company Overview
    • 8.14.2. Drug Overview
    • 8.14.3. Clinical Development Status
    • 8.14.4. Key Insights
    • 8.14.5. Sales Revenue
  • 8.15. Foscan(R) (Temoporfin)
    • 8.15.1. Company Overview
    • 8.15.2. Drug Overview
    • 8.15.3. Clinical Development Status
    • 8.15.4. Clinical Trial Endpoints
    • 8.15.5. Dosage Regimen
    • 8.15.6. Key Insights
    • 8.15.7. Sales Revenue
  • 8.16. FuMeiDa(R) (Hemoporfin)
    • 8.16.1. Company Overview
    • 8.16.2. Drug Overview
    • 8.16.3. Clinical Development Status
    • 8.16.4. Clinical Trial Endpoints
    • 8.16.5. Dosage Regimen
    • 8.16.6. Key Insights
    • 8.16.16. Sales Revenue
  • 8.17. Levulan Kerastick(R)
    • 8.17.1. Company Overview
    • 8.17.2. Drug Overview
    • 8.17.3. Clinical Development Status
    • 8.17.4. Dosage Regimen
    • 8.17.5. Key Insights
    • 8.17.6. Sales Revenue
  • 8.18. Metvixia(R) (Metvix)
    • 8.18.1. Company Overview
    • 8.18.2. Drug Overview
    • 8.18.3. Clinical Development Status
    • 8.18.4. Clinical Trial Endpoints
    • 8.18.5. Dosage Regimen
    • 8.18.6. Key Insights
    • 8.18.7. Sales Revenue
  • 8.19. Porfimer Sodium / Photofrin(R)
    • 8.19.1. Company Overview
    • 8.19.2. Drug Overview
    • 8.19.3. Clinical Development Status
    • 8.19.4. Clinical Trial Endpoints
    • 8.19.5. Dosage Regimen
    • 8.19.6. Sales Revenue
  • 8.20. Verteporfin(R) (Visudyne)
    • 8.20.1. Company Overview
    • 8.20.2. Drug Overview
    • 8.20.3. Clinical Development Status
    • 8.20.4. Clinical Trial Endpoints
    • 8.20.5. Dosage Regimen
    • 8.20.6. Key Insights
    • 8.20.7. Sales Revenue

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Light Activated Therapies: Clinical Trial Analysis
    • 9.3.1. Analysis by Trial Registration Year
    • 9.3.2. Analysis of Patients Enrolled by Trial Registration Year
    • 9.3.3. Analysis by Trial Phase
    • 9.3.4. Analysis of Patients Enrolled by Trial Phase
    • 9.3.5. Analysis by Trial Status
    • 9.3.6. Analysis by Trial Registration Year and Trial Status
    • 9.3.7. Analysis of Patients Enrolled by Trial Status
    • 9.3.8. Analysis by Target Patient Population
    • 9.3.9. Analysis by Patient Gender
    • 9.3.10. Analysis by Type of Sponsor / Collaborator
    • 9.3.11. Analysis by Study Design
      • 9.3.11.1. Analysis by Type of Patient Allocation Model Used
      • 9.3.11.2. Analysis by Type of Trial Masking Adopted
      • 9.3.11.3. Analysis by Type of Trial Intervention Model
      • 9.3.11.4. Analysis by Trial Purpose
    • 9.3.12. Most Active Players: Analysis by Number of Clinical Trials
    • 9.3.13. Analysis by Geography
      • 9.3.13.1. Analysis of Clinical Trials by Geography
      • 9.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
      • 9.3.13.3. Analysis of Clinical Trials by Geography and Trial Phase
      • 9.3.13.4. Analysis of Patients Enrolled by Geography
      • 9.3.13.5. Analysis of Patients Enrolled by Geography and Trial Status

10. PATENT ANALYSIS

  • 10.1 Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Light Activated Therapies: Patent Analysis
    • 10.3.1. Analysis by Type of Patent
    • 10.3.2. Analysis by Publication Year
    • 10.3.3. Analysis by Type of Patent and Publication Year
    • 10.3.4. Analysis by Application Year
    • 10.3.5. Analysis by Jurisdiction
    • 10.3.6. Analysis by Type of Applicant
    • 10.3.7. Analysis by Patent Age
    • 10.3.8. Analysis by CPC Symbols
    • 10.3.9. Leading Industry Players: Analysis by Number of Patents
    • 10.3.10. Leading Non-Industry Players: Analysis by Number of Patents
    • 10.3.11. Leading Inventors: Analysis by Number of Patents
  • 10.4. Light Activated Therapies: Patent Benchmarking Analysis
    • 10.4.1. Analysis by Patent Characteristics
    • 10.4.2. Analysis by Leading Industry Players
  • 10.5. Patent Valuation Analysis

11. MARKET IMPACT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Market Drivers
  • 11.3. Market Restraints
  • 11.4. Market Opportunities
  • 11.5. Market Challenges
  • 11.6. Conclusion

12. GLOBAL PHOTODYNAMIC THERAPY MARKET

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Methodology
  • 12.3. Global Photodynamic Therapy Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 12.3.1. Roots Analysis Perspective on Market Growth
    • 12.3.2. Scenario Analysis
      • 12.3.2.1. Conservative Scenario
      • 12.3.2.2. Optimistic Scenario
  • 12.4. Key Market Segmentations

13. PHOTODYNAMIC THERAPY MARKET, BY TARGET INDICATION

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Photodynamic Therapy Market: Distribution by Target Indication
    • 13.3.1. Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.2. Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.3. Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.4. Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.5. Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.6. Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.7. Photodynamic Therapy Market for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.8. Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.9. Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.10. Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.11. Photodynamic Therapy Market for Bowen's Disease, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.11. Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.12. Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.13. Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 13.3.14. Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 13.4. Data Triangulation and Validation

14. PHOTODYNAMIC THERAPY MARKET, BY THERAPEUTIC AREA

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Photodynamic Therapy Market: Distribution by Therapeutic Area
    • 14.3.1. Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 14.3.2. Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 14.3.3. Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  • 14.4. Data Triangulation and Validation

15. PHOTODYNAMIC THERAPY MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Photodynamic Therapy Market: Distribution by Key Geographical Regions
    • 15.3.1. Photodynamic Therapy Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.1.1. Photodynamic Therapy Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.1.2. Photodynamic Therapy Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 15.3.2. Photodynamic Therapy Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.1. Photodynamic Therapy Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.2. Photodynamic Therapy Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.3. Photodynamic Therapy Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.4. Photodynamic Therapy Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.5. Photodynamic Therapy Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.2.6. Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 15.3.3. Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.3.1. Photodynamic Therapy Market in India, Forecasted Estimates (till 2035)
      • 15.3.3.2. Photodynamic Therapy Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.3.3. Photodynamic Therapy Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
    • 15.3.4. Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
      • 15.3.4.1. Photodynamic Therapy Market in Israel, Forecasted Estimates (till 2035)
  • 15.4. Market Dynamics Assessment: Key Geographical Regions
    • 15.4.1. Penetration Growth (P-G) Matrix
    • 15.4.2. Market Movement Analysis
  • 15.5. Data Triangulation and Validation

16. CONCLUDING REMARKS

17. EXECUTIVE INSIGHTS

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHY

20. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 20.1. Photodynamic Therapy Market in North America: Distribution by Target Indication
    • 20.1.1. Photodynamic Therapy Market in North America for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.2. Photodynamic Therapy Market in North America for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.3. Photodynamic Therapy Market in North America for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.4. Photodynamic Therapy Market in North America for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.5. Photodynamic Therapy Market in North America for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.6. Photodynamic Therapy Market in North America for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.7. Photodynamic Therapy Market in North America for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.8. Photodynamic Therapy Market in North America for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.9. Photodynamic Therapy Market in North America for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.10. Photodynamic Therapy Market in North America for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.11. Photodynamic Therapy Market in North America for Bowen's Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.12. Photodynamic Therapy Market in North America for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.13. Photodynamic Therapy Market in North America for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.14. Photodynamic Therapy Market in North America for T-cell Lymphoma Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.1.15. Photodynamic Therapy Market in North America for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
  • 20.2. Photodynamic Therapy Market in North America: Distribution by Therapeutic Area
    • 20.2.1. Photodynamic Therapy Market in North America for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.2.2. Photodynamic Therapy Market in North America for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 20.2.3. Photodynamic Therapy Market in North America for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)

21. MARKET OPPORTUNITY ANALYSIS: EUROPE

  • 21.1. Photodynamic Therapy Market in Europe: Distribution by Target Indication
    • 21.1.1. Photodynamic Therapy Market in Europe for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.2. Photodynamic Therapy Market in Europe for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.3. Photodynamic Therapy Market in Europe for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.4. Photodynamic Therapy Market in Europe for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.5. Photodynamic Therapy Market in Europe for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.6. Photodynamic Therapy Market in Europe for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.7. Photodynamic Therapy Market in Europe for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.8. Photodynamic Therapy Market in Europe for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.9. Photodynamic Therapy Market in Europe for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.10. Photodynamic Therapy Market in Europe for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.11. Photodynamic Therapy Market in Europe for Bowen's Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.12. Photodynamic Therapy Market in Europe for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.13. Photodynamic Therapy Market in Europe for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.14. Photodynamic Therapy Market in Europe for T-cell Lymphoma Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.1.15. Photodynamic Therapy Market in Europe for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
  • 21.2. Photodynamic Therapy Market in Europe: Distribution by Therapeutic Area
    • 21.2.1. Photodynamic Therapy Market in Europe for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.2.2. Photodynamic Therapy Market in Europe for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 21.2.3. Photodynamic Therapy Market in Europe for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)

22. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

  • 22.1. Photodynamic Therapy Market in Asia-Pacific: Distribution by Target Indication
    • 22.1.1. Photodynamic Therapy Market in Asia-Pacific for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.2. Photodynamic Therapy Market in Asia-Pacific for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.3. Photodynamic Therapy Market in Asia-Pacific for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.4. Photodynamic Therapy Market in Asia-Pacific for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.5. Photodynamic Therapy Market in Asia-Pacific for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.6. Photodynamic Therapy Market in Asia-Pacific for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.7. Photodynamic Therapy Market in Asia-Pacific for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.8. Photodynamic Therapy Market in Asia-Pacific for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.9. Photodynamic Therapy Market in Asia-Pacific for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.10. Photodynamic Therapy Market in Asia-Pacific for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.11. Photodynamic Therapy Market in Asia-Pacific for Bowen's Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.12. Photodynamic Therapy Market in Asia-Pacific for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.13. Photodynamic Therapy Market in Asia-Pacific for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.14. Photodynamic Therapy Market in Asia-Pacific for T-cell Lymphoma Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.1.15. Photodynamic Therapy Market in Asia-Pacific for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
  • 22.2. Photodynamic Therapy Market in Asia-Pacific: Distribution by Therapeutic Area
    • 22.2.1. Photodynamic Therapy Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.2.2. Photodynamic Therapy Market in Asia-Pacific for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 22.2.3. Photodynamic Therapy Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)

23. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

  • 23.1. Photodynamic Therapy Market in Middle East and North Africa: Distribution by Target Indication
    • 23.1.1. Photodynamic Therapy Market in Middle East and North Africa for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.2. Photodynamic Therapy Market in Middle East and North Africa for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.3. Photodynamic Therapy Market in Middle East and North Africa for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.4. Photodynamic Therapy Market in Middle East and North Africa for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.5. Photodynamic Therapy Market in Middle East and North Africa for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.6. Photodynamic Therapy Market in Middle East and North Africa for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.7. Photodynamic Therapy Market in Middle East and North Africa for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.8. Photodynamic Therapy Market in Middle East and North Africa for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.9. Photodynamic Therapy Market in Middle East and North Africa for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.10. Photodynamic Therapy Market in Middle East and North Africa for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.11. Photodynamic Therapy Market in Middle East and North Africa for Bowen's Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.12. Photodynamic Therapy Market in Middle East and North Africa for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.13. Photodynamic Therapy Market in Middle East and North Africa for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.14. Photodynamic Therapy Market in Middle East and North Africa for T-cell Lymphoma Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.1.15. Photodynamic Therapy Market in Middle East and North Africa for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
  • 23.2. Photodynamic Therapy Market in Middle East and North Africa: Distribution by Therapeutic Area
    • 23.2.1. Photodynamic Therapy Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.2.2. Photodynamic Therapy Market in Middle East and North Africa for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)
    • 23.2.3. Photodynamic Therapy Market in Middle East and North Africa for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (Till 2035)

*Detailed information on Chapter 20-23 is available in the Excel Data Packs shared along with the report**

List of Tables

  • Table 7.2 Light Activated Therapies: Information on Drug Pipeline, Type of Light Activated Therapy and Stage of Development
  • Table 7.3 Light Activated Therapies: Information on Type of Light Used, Type of Therapy, Dosing Frequency, Target Indication and Therapeutic Area
  • Table 7.1 Light Activated Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters
  • Table 8.1 Light Activated Therapies: List of Companies Profiles
  • Table 8.2 ADVANZ PHARMA: Company Snapshot
  • Table 8.3 ADVANZ PHARMA: Product Portfolio
  • Table 8.4 ADVANZ PHARMA: Recent Developments and Future Outlook
  • Table 8.5 Biofrontera: Company Snapshot
  • Table 8.6 Biofrontera: Product Portfolio
  • Table 8.7 Biofrontera: Recent Developments and Future Outlook
  • Table 8.8 biolitec Pharma: Company Snapshot
  • Table 8.9 biolitec Pharma: Product Portfolio
  • Table 8.10 biolitec Pharma: Recent Developments and Future Outlook
  • Table 8.11 Luzitin: Company Snapshot
  • Table 8.12 Luzitin: Product Portfolio
  • Table 8.13 Luzitin: Recent Developments and Future Outlook
  • Table 8.14 Nanospectra Biosciences: Company Snapshot
  • Table 8.15 Nanospectra Biosciences: Product Portfolio
  • Table 8.16 Nanospectra Biosciences: Recent Developments and Future Outlook
  • Table 8.17 photoatomic: Company Snapshot
  • Table 8.18 photoatomic: Product Portfolio
  • Table 8.19 photoatomic: Recent Developments and Future Outlook
  • Table 8.20 Rakuten Medical: Company Snapshot
  • Table 8.21 Rakuten Medical: Product Portfolio
  • Table 8.22 Rakuten Medical: Recent Developments and Future Outlook
  • Table 8.23 Impact Biotech: Company Snapshot
  • Table 8.24 Impact Biotech: Product Portfolio
  • Table 8.25 Impact Biotech: Recent Developments and Future Outlook
  • Table 8.26 Theralase: Company Snapshot
  • Table 8.27 Theralase: Product Portfolio
  • Table 8.28 Theralase: Recent Developments and Future Outlook
  • Table 8.29 Cetuximab Sarotalocan(R): Clinical Developmental Status
  • Table 8.30 Cetuximab Sarotalocan(R): Clinical Trial Endpoints
  • Table 8.31 Cetuximab Sarotalocan(R): Dosage Regimen
  • Table 8.32 Cetuximab Sarotalocan(R): Key Insights
  • Table 8.33 Alacare(R): Clinical Developmental Status
  • Table 8.34 Alacare(R): Clinical Trial Endpoints
  • Table 8.35 Alacare(R): Dosage Regimen
  • Table 8.36 Alacare(R): Key Insights
  • Table 8.37 Ameluz(R): Clinical Developmental Status
  • Table 8.38 Ameluz(R): Clinical Trial Endpoints
  • Table 8.39 Ameluz(R): Dosage Regimen
  • Table 8.40 Ameluz(R): Key Insights
  • Table 8.41 Aminolevulinic Acid: Clinical Developmental Status
  • Table 8.42 Aminolevulinic Acid: Key Insights
  • Table 8.43 Foscan(R) (Temoporfin): Clinical Developmental Status
  • Table 8.44 Foscan(R) (Temoporfin): Clinical Trial Endpoints
  • Table 8.45 Foscan(R) (Temoporfin): Dosage Regimen
  • Table 8.46 Foscan(R) (Temoporfin): Key Insights
  • Table 8.47 FuMeiDa(R) (Hemoporfin): Clinical Developmental Status
  • Table 8.48 FuMeiDa(R) (Hemoporfin): Clinical Trial Endpoints
  • Table 8.49 FuMeiDa(R) (Hemoporfin): Dosage Regimen
  • Table 8.50 FuMeiDa(R) (Hemoporfin): Key Insights
  • Table 8.51 Levulan Kerastick(R): Clinical Developmental Status
  • Table 8.52 Levulan Kerastick(R): Clinical Trial Endpoints
  • Table 8.53 Levulan Kerastick(R): Dosage Regimen
  • Table 8.54 Levulan Kerastick(R): Key Insights
  • Table 8.55 Metvixia(R) (Metvix): Clinical Developmental Status
  • Table 8.56 Metvixia(R) (Metvix): Clinical Trial Endpoints
  • Table 8.57 Metvixia(R) (Metvix): Dosage Regimen
  • Table 8.58 Metvixia(R) (Metvix): Key Insights
  • Table 8.59 Porfimer Sodium / Photofrin(R): Clinical Developmental Status
  • Table 8.60 Porfimer Sodium / Photofrin(R): Clinical Trial Endpoints
  • Table 8.61 Porfimer Sodium / Photofrin(R): Dosage Regimen
  • Table 8.62 Verteporfin(R) (Visudyne): Clinical Developmental Status
  • Table 8.63 Verteporfin(R) (Visudyne): Clinical Trial Endpoints
  • Table 8.64 Verteporfin(R) (Visudyne): Dosage Regimen
  • Table 8.65 Verteporfin(R) (Visudyne): Key Insights
  • Table 10.1 Patent Analysis: Top CPC Sections
  • Table 10.2 Patent Analysis: Top CPC Symbols
  • Table 10.3 Patent Analysis: Top CPC Codes
  • Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 10.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
  • Table 19.1 Light Activated Therapies: Distribution by Type of Light Activated Therapy
  • Table 19.2 Light Activated Therapies: Distribution by Stage of Development
  • Table 19.3 Light Activated Therapies: Distribution by Type of Light Used
  • Table 19.4 Light Activated Therapies: Distribution by Type of Therapy
  • Table 19.5 Light Activated Therapies: Distribution by Dosing Frequency
  • Table 19.6 Light Activated Therapies: Distribution by Target Indication
  • Table 19.7 Light Activated Therapies: Distribution by Therapeutic Area
  • Table 19.8 Light Activated Therapies: Distribution by Therapeutic Area and Stage of Development
  • Table 19.9 Light Activated Therapy Developers: Distribution by Year of Establishment
  • Table 19.10 Light Activated Therapy Developers: Distribution by Company Size
  • Table 19.11 Light Activated Therapy Developers: Distribution by Location of Headquarters (Region)
  • Table 19.12 Light Activated Therapy Developers: Distribution by Location of Headquarters (Country)
  • Table 19.13 ADVANZ PHARMA: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.14 Biofrontera: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.15 biolitec Pharma: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.16 Luzitin: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.17 Nanospectra Biosciences: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.18 photoatomic: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.19 Rakuten Medical: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.20 Impact Biotech: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.21 Theralase: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Table 19.22 Cetuximab Sarotalocan(R): Sales Revenue
  • Table 19.23 Alacare(R): Sales Revenue
  • Table 19.24 Ameluz(R): Sales Revenue
  • Table 19.25 Aminolevulinic Acid: Sales Revenue
  • Table 19.26 Foscan(R) (Temoporfin): Sales Revenue
  • Table 19.27 FuMeiDa(R) (Hemoporfin): Sales Revenue
  • Table 19.28 Levulan Kerastick(R): Sales Revenue
  • Table 19.29 Metvixia(R) (Metvix): Sales Revenue
  • Table 19.30 Porfimer Sodium / Photofrin(R): Sales Revenue
  • Table 19.31 Verteporfin(R) (Visudyne): Sales Revenue
  • Table 19.32 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2021
  • Table 19.33 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2021
  • Table 19.34 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 19.35 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
  • Table 19.36 Clinical Trial Analysis: Distribution by Trial Status
  • Table 19.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 19.38 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status
  • Table 19.39 Clinical Trial Analysis: Distribution by Target Patient Population
  • Table 19.40 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 19.41 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 19.42 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
  • Table 19.43 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
  • Table 19.44 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 19.45 Clinical Trial Analysis: Distribution by Trial Purpose
  • Table 19.46 Most Active Industry Players: Distribution by Number of Clinical Trials
  • Table 19.47 Most Active Non-Industry Players: Distribution by Number of Clinical Trials
  • Table 19.48 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 19.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
  • Table 19.50 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Phase
  • Table 19.51 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
  • Table 19.52 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
  • Table 19.53 Patent Analysis: Distribution by Type of Patent
  • Table 19.54 Patent Analysis: Distribution by Patent Publication Year
  • Table 19.55 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Table 19.56 Patent Analysis: Distribution by Patent Application Year
  • Table 19.57 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 19.58 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Table 19.59 Patent Analysis: Distribution by Patent Age
  • Table 19.60 Leading Industry Players: Distribution by Number of Patents
  • Table 19.61 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 19.62 Leading Inventors: Distribution by Number of Patents
  • Table 19.63 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Table 19.64 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Table 19.65 Light Activated Therapies: Patent Valuation
  • Table 19.66 Global Photodynamic Therapy Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
  • Table 19.67 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Table 19.68 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Table 19.69 Global Photodynamic Therapy Market: Distribution by Target Indication
  • Table 19.70 Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.71 Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.72 Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.73 Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.74 Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.75 Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.76 Photodynamic Therapy Market for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.77 Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.78 Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.79 Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.80 Photodynamic Therapy Market for Bowen's Disease, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.81 Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.82 Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.83 Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.84 Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.85 Photodynamic Therapy Market: Distribution by Therapeutic Area
  • Table 19.86 Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.87 Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.88 Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.89 Photodynamic Therapy Market: Distribution by Key Geographical Regions
  • Table 19.90 Photodynamic Therapy Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.91 Photodynamic Therapy Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.92 Photodynamic Therapy Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.93 Photodynamic Therapy Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.94 Photodynamic Therapy Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.95 Photodynamic Therapy Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.96 Photodynamic Therapy Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.97 Photodynamic Therapy Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.98 Photodynamic Therapy Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.99 Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.100 Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.101 Photodynamic Therapy Market in India, Forecasted Estimates (till 2035) (USD Million)
  • Table 19.102 Photodynamic Therapy Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.103 Photodynamic Therapy Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.104 Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 19.105 Photodynamic Therapy Market in Israel, and Forecasted Estimates (till 2035) (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Key Market Segmentation
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Overall Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 6.1 Type of Light Activated Therapy
  • Figure 6.2 Mechanism of Action of Photoimmunotherapies
  • Figure 6.3 Mechanism of Action of Photodynamic Therapy
  • Figure 6.4 Advantages and Challenges associated with Photodynamic Therapy
  • Figure 6.5 Mechanism of Action of Photothermal Therapy
  • Figure 7.1 Light Activated Therapies: Distribution by Type of Light Activated Therapy
  • Figure 7.2 Light Activated Therapies: Distribution by Stage of Development
  • Figure 7.3 Light Activated Therapies: Distribution by Type of Light Used
  • Figure 7.4 Light Activated Therapies: Distribution by Type of Therapy
  • Figure 7.5 Light Activated Therapies: Distribution by Dosing Frequency
  • Figure 7.6 Light Activated Therapies: Distribution by Target Indication
  • Figure 7.7 Light Activated Therapies: Distribution by Therapeutic Area
  • Figure 7.8 Light Activated Therapies: Distribution by Therapeutic Area and Stage of Development
  • Figure 7.9 Light Activated Therapy Developers: Distribution by Year of Establishment
  • Figure 7.10 Light Activated Therapy Developers: Distribution by Company Size
  • Figure 7.11 Light Activated Therapy Developers: Distribution by Location of Headquarters (Region)
  • Figure 7.12 Light Activated Therapy Developers: Distribution by Location of Headquarters (Country)
  • Figure 8.1 ADVANZ PHARMA: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.2 Biofrontera: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.3 biolitec Pharma: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.4 Luzitin: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.5 Nanospectra Biosciences: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.6 photoatomic: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.7 Rakuten Medical: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.8 Impact Biotech: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.9 Theralase: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021
  • Figure 8.10 Cetuximab Sarotalocan(R): Sales Revenue
  • Figure 8.11 Alacare(R): Sales Revenue
  • Figure 8.12 Ameluz(R): Sales Revenue
  • Figure 8.13 Aminolevulinic Acid: Sales Revenue
  • Figure 8.14 Foscan(R) (Temoporfin): Sales Revenue
  • Figure 8.15 FuMeiDa(R) (Hemoporfin): Sales Revenue
  • Figure 8.16 Levulan Kerastick(R): Sales Revenue
  • Figure 8.17 Metvixia(R) (Metvix): Sales Revenue
  • Figure 8.18 Porfimer Sodium / Photofrin(R): Sales Revenue
  • Figure 8.19 Verteporfin(R) (Visudyne): Sales Revenue
  • Figure 9.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2021
  • Figure 9.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2021
  • Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 9.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
  • Figure 9.5 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 9.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 9.7 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status
  • Figure 9.8 Clinical Trial Analysis: Distribution by Target Patient Population
  • Figure 9.9 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 9.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 9.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
  • Figure 9.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
  • Figure 9.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 9.14 Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 9.15 Most Active Industry Players: Distribution by Number of Clinical Trials
  • Figure 9.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials
  • Figure 9.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Figure 9.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
  • Figure 9.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Phase
  • Figure 9.20 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
  • Figure 9.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Distribution by Patent Publication Year
  • Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year
  • Figure 10.4 Patent Analysis: Distribution by Patent Application Year
  • Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 10.6 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant
  • Figure 10.7 Patent Analysis: Distribution by Patent Age
  • Figure 10.8 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.11 Leading Inventors: Distribution by Number of Patents
  • Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 10.13 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 10.14 Light Activated Therapies: Patent Valuation
  • Figure 12.1 Global Light Activated Therapies Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035): Base Scenario (USD Million)
  • Figure 12.2 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Figure 12.3 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Figure 13.1 Photodynamic Therapy Market: Distribution by Target Indication
  • Figure 13.2 Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.3 Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.4 Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.5 Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.6 Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.7 Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.8 Photodynamic Therapy Market for Barrett's Esophagus, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.9 Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.10 Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.11 Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.12 Photodynamic Therapy Market for Bowen's Disease, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.13 Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.14 Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.15 Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.16 Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.1 Photodynamic Therapy Market: Distribution by Therapeutic Area
  • Figure 14.2 Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.3 Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.4 Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.1 Photodynamic Therapy Market: Distribution by Key Geographical Regions
  • Figure 15.2 Photodynamic Therapy Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.3 Photodynamic Therapy Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.4 Photodynamic Therapy Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.5 Photodynamic Therapy Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.6 Photodynamic Therapy Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.7 Photodynamic Therapy Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.8 Photodynamic Therapy Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.9 Photodynamic Therapy Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.10 Photodynamic Therapy Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.11 Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.12 Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.13 Photodynamic Therapy Market in India, Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.14 Photodynamic Therapy Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.15 Photodynamic Therapy Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.16 Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.17 Photodynamic Therapy Market in Israel, Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.18 Penetration Growth (P-G) Matrix: Key Geographical Regions
  • Figure 15.19 Market Movement Analysis: Key Geographical Regions
  • Figure 16.1 Concluding Remarks: Light Activated Therapy Developers
  • Figure 16.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 16.3 Concluding Remarks: Patent Analysis
  • Figure 16.4 Concluding Remarks: Market Forecast and Opportunity Analysis